These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 30243708

  • 1. PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.
    De Martino D, Yilmaz E, Orlacchio A, Ranieri M, Zhao K, Di Cristofano A.
    Cancer Lett; 2018 Dec 28; 439():56-65. PubMed ID: 30243708
    [Abstract] [Full Text] [Related]

  • 2. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
    Russo MA, Kang KS, Di Cristofano A.
    Thyroid; 2013 Oct 28; 23(10):1284-93. PubMed ID: 23509868
    [Abstract] [Full Text] [Related]

  • 3. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
    Stehle A, Hugle M, Fulda S.
    Cancer Lett; 2015 Aug 28; 365(1):37-46. PubMed ID: 25917079
    [Abstract] [Full Text] [Related]

  • 4. Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1.
    Jemaà M, Kifagi C, Serrano SS, Massoumi R.
    Cell Physiol Biochem; 2020 Apr 08; 54(2):303-320. PubMed ID: 32259417
    [Abstract] [Full Text] [Related]

  • 5. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.
    Nappi TC, Salerno P, Zitzelsberger H, Carlomagno F, Salvatore G, Santoro M.
    Cancer Res; 2009 Mar 01; 69(5):1916-23. PubMed ID: 19223553
    [Abstract] [Full Text] [Related]

  • 6. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
    Zhu X, Park S, Lee WK, Cheng SY.
    Endocr Relat Cancer; 2019 Sep 01; 26(9):739-750. PubMed ID: 31272080
    [Abstract] [Full Text] [Related]

  • 7. BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.
    Chen E, Pei R.
    J Int Med Res; 2020 May 01; 48(5):300060520926093. PubMed ID: 32468878
    [Abstract] [Full Text] [Related]

  • 8. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
    Wang Y, Hu Z, Ma W, Niu Y, Su J, Zhang L, Zhao P.
    Invest New Drugs; 2021 Jun 01; 39(3):764-774. PubMed ID: 33245464
    [Abstract] [Full Text] [Related]

  • 9. PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.
    Wong K, Di Cristofano F, Ranieri M, De Martino D, Di Cristofano A.
    Endocr Relat Cancer; 2019 Apr 01; 26(4):425-436. PubMed ID: 30699064
    [Abstract] [Full Text] [Related]

  • 10. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
    Sadowski SM, Boufraqech M, Zhang L, Mehta A, Kapur P, Zhang Y, Li Z, Shen M, Kebebew E.
    Oncotarget; 2015 Jul 20; 6(20):18038-49. PubMed ID: 25945839
    [Abstract] [Full Text] [Related]

  • 11. Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs.
    Hugle M, Belz K, Fulda S.
    Cell Death Differ; 2015 Dec 20; 22(12):1946-56. PubMed ID: 26024389
    [Abstract] [Full Text] [Related]

  • 12. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
    Zuco V, De Cesare M, Zaffaroni N, Lanzi C, Cassinelli G.
    Oncotarget; 2015 Apr 20; 6(11):8736-49. PubMed ID: 25826089
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
    Wang NY, Xu Y, Xiao KJ, Zuo WQ, Zhu YX, Hu R, Wang WL, Shi YJ, Yu LT, Liu ZH.
    Eur J Med Chem; 2020 Apr 01; 191():112152. PubMed ID: 32088495
    [Abstract] [Full Text] [Related]

  • 14. PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs.
    Brassesco MS, Pezuk JA, Salomão KB, Roberto GM, Scrideli CA, Tone LG.
    Anticancer Agents Med Chem; 2018 Apr 01; 18(9):1252-1257. PubMed ID: 29493466
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
    Spartà AM, Bressanin D, Chiarini F, Lonetti A, Cappellini A, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Martelli AM.
    Cell Cycle; 2014 Apr 01; 13(14):2237-47. PubMed ID: 24874015
    [Abstract] [Full Text] [Related]

  • 16. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M, Singh R, Peng S, Mazumdar T, Sambandam V, Shen L, Tong P, Li L, Kalu NN, Pickering CR, Frederick M, Myers JN, Wang J, Johnson FM.
    Cancer Lett; 2017 Apr 28; 392():71-82. PubMed ID: 28126323
    [Abstract] [Full Text] [Related]

  • 17. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM.
    Oncotarget; 2016 Jul 26; 7(30):47998-48010. PubMed ID: 27384992
    [Abstract] [Full Text] [Related]

  • 18. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
    Abbou S, Lanvers-Kaminsky C, Daudigeos-Dubus E, LE Dret L, Laplace-Builhe C, Molenaar J, Vassal G, Geoerger B, within the ITCC Biology and Preclinical Evaluation Committee.
    Anticancer Res; 2016 Feb 26; 36(2):599-609. PubMed ID: 26851014
    [Abstract] [Full Text] [Related]

  • 19. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
    Xu L, Zhu Y, Shao J, Chen M, Yan H, Li G, Zhu Y, Xu Z, Yang B, Luo P, He Q.
    Br J Cancer; 2017 Apr 11; 116(8):1027-1036. PubMed ID: 28267710
    [Abstract] [Full Text] [Related]

  • 20. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ.
    Endocrine; 2016 Feb 11; 51(2):274-82. PubMed ID: 26219406
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.